NAD makes two supplement recommendations
NEW YORK The National Advertising Division of the Council of Better Business Bureaus made a pair recommendations last week regarding dietary supplement advertising.
NAD recommended that Bioforce USA modify or discontinue advertising claims for its Sanhelios Curbita Bladder Caps dietary supplement that suggest the product “strengthen” the bladder. However, NAD found reasonable support for claims that the product could “support” or “enhance” bladder function. NAD also found that the advertiser’s claim of “uniqueness” was supported.
Bioforce, in its advertiser’s statement, indicated that it “is gratified that the NAD concluded that the claims for Sanhelios Curbita Bladder Caps to support and enhance bladder function are substantiated”, “its uniqueness claims are supported,” and that “claims to strengthen the bladder are also appropriate as long as properly qualified.”
NAD also reviewed the advertising of New Charter Distribution, recommending that the company modify or discontinue several advertising claims for its Blockade brand dietary supplement, including that the product blocks viruses like influenza from entering and infecting human cells within minutes of use.
Blockade’s active dietary ingredient is “ViraBloc,” an elderberry extract developed by HerbalScience Nutraceuticals.
At the outset of the NAD inquiry, the advertiser represented that it would discontinue certain claims at issue and modify the claim “BLOCKS & LOCKS VIRUSES … COLD.” NAD concluded that the advertiser could continue to make certain claims about Blockade’s mechanism of action, as long as they are limited and properly qualified, and do not suggest or imply disease treatment or prevention.
The company, in its advertiser’s statement, said it agrees “to take into consideration all of the recommendations of NAD in all future national advertising of Blockade intended for sale to consumers in the United States, and will follow NAD’s recommendation to inform those online retailers which are advertising Blockade of this decision, including the recommendations in this decision.”
Both challenges were brought to NAD by the Council for Responsible Nutrition.
Study suggests green tea effective on HPV-related warts
NEW YORK A study published in the June issue of the Journal of Obstetrics and Gynecology has found that the green tea extract sinecatechins is useful for treating genital and anal warts.
The study found that 57 percent of patients who received ointment containing 10 or 15 percent sinecatechins were cleared of warts, compared to 34 percent of patients in the control group. Warts in at least three quarters of patients were cleared by at least 50 percent, compared to about half of patients in the control group.
The study examined 502 adults with between two and 30 warts over a 16-week period or until warts cleared.
Genital warts are caused by the human papillomavirus, also known as HPV and increase the risk of cervical cancer in women.
NBTY proposes $230 million buyout of Leiner
RONKONKOMA, N.Y. NBTY on May 30 proposed buying troubled private-label manufacturer Leiner Health Products in a deal worth $230 million plus the assumption of certain liabilities, according to an NBTY SEC filing.
The proposed buyout of Leiner, which filed for bankruptcy protection March 10, will be subject to higher or better offers and if any are proffered, the ownership of Leiner Health will be decided at a June 9 auction
If no higher or better offer is submitted by a competing bidder, the purchase transaction is expected to close no later than September.
Leiner in March filed its second bankruptcy in seven years, and is also emerging from a manufacturing scandal, in which the company last month pled guilty to mail fraud and forfeited $10 million to close the chapter on a U.S. Department of Justice investigation into Leiner’s now-closed Fort Mill, S.C. production facility following a Food and Drug Administration warning letter that “found many serious deviations [at that facility], some of which involved data manipulation and inadequate testing procedures.” The FDA concluded that “the products manufactured at [the Leiner] facility under these violative conditions put consumers at significant risk.”
Early last year, Leiner had stopped making over-the-counter drugs at that facility. In addition, Robert Kaminski resigned as company chief executive officer and was succeeded by Robert Reynolds.
The recent agreement in no way implicates or affects Leiner’s ability to manufacture and distribute vitamin and mineral products, the company stated.